Compositions with nerve regeneration applications
JP2023532557A5Inactive Publication Date: 2026-06-22GRIFOLS WORLDWIDE OPERATIONS
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- JP2022581608
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-07-08
- Filing Date
- 2021-07-07
- Publication Date
- 2026-06-22
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Technical Problem
Current treatments for neurodegenerative diseases such as amyotrophic lateral sclerosis, Huntington's disease, Alzheimer's disease, and Parkinson's disease primarily focus on symptom management and neuroprotection, lacking therapies that can cure or reverse neuronal damage.
Method used
Administration of transferrin and lactoferrin, either wild-type or recombinant variants, with low iron saturation, to promote neuronal proliferation and differentiation, enhancing the body's nerve regeneration and repair mechanisms.
Benefits of technology
Transferrin and lactoferrin stimulate neuronal development by promoting the generation of new neurons, potentially reversing neuronal damage and improving neurological function in patients with neurodegenerative diseases.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 00000000_0000_ABST
Abstract
Disclosed herein is a pharmaceutical composition containing transferrin or lactoferrin for use in promoting or inducing the generation of new nerve cells in patients suffering from neurodegenerative events. Neurodegenerative events may be caused by neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Huntington's disease, or amyotrophic lateral sclerosis. Ideally, the transferrin and / or lactoferrin has low iron saturation.
Need to check novelty before this filing date? Find Prior Art